Your browser doesn't support javascript.
loading
Atypical BCR-ABL1 transcript in mixed phenotype acute leukemia with bone marrow necrosis.
Liu, Jiarui; Jiang, Yujie; Yuan, Dai; Zhang, Zhifen; Liu, Xin; Zhao, Wenbo; Xu, Hongzhi.
Affiliation
  • Liu J; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Jiang Y; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Yuan D; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Zhang Z; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Liu X; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Zhao W; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Xu H; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Mol Carcinog ; 63(8): 1429-1435, 2024 Aug.
Article de En | MEDLINE | ID: mdl-38860593
ABSTRACT
Mixed phenotype acute leukemia (MPAL) is a type of acute leukemia in which encompasses mixed features of myeloid, T-lymphoid, and/or B-lymphoid differentiation. Philadelphia chromosome-positive (Ph+) MPAL is a rare subgroup with a poor prognosis and accounts for <1% of adult acute leukemia. Until now, there is still no consensus on how to best treat Ph+ MPAL. Here, we report a 62-year-old male with Ph+ (atypical e13a2 BCR-ABL1 fusion protein) MPAL. This patient presented with recurrent and intense bone pain due to bone marrow necrosis (BMN). Besides, he did not achieve a complete remission for the first two chemotherapies, until he received flumatinib combined with hyper-CVAD (B) (a dose-intensive regimen include methotrexate and cytarabine). To our knowledge, this is the first report to describe the coexistence of BMN and atypical e13a2 BCR-ABL1 transcripts in patients with MPAL. This finding will bring new understandings in the diagnosis and treatment of Ph+ MPAL.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Moelle osseuse / Protéines de fusion bcr-abl / Nécrose Limites: Humans / Male / Middle aged Langue: En Journal: Mol Carcinog / Mol. Carcinog / Molecular carcinogenesis Sujet du journal: BIOLOGIA MOLECULAR / NEOPLASIAS Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Moelle osseuse / Protéines de fusion bcr-abl / Nécrose Limites: Humans / Male / Middle aged Langue: En Journal: Mol Carcinog / Mol. Carcinog / Molecular carcinogenesis Sujet du journal: BIOLOGIA MOLECULAR / NEOPLASIAS Année: 2024 Type de document: Article Pays d'affiliation: Chine Pays de publication: États-Unis d'Amérique